Itolizumab

From Wikipedia, the free encyclopedia
Itolizumab ?
Monoclonal antibody
Type Whole antibody
Source Humanized
Target CD6
Clinical data
Trade names Alzumab
Legal status Approved in India
Identifiers
CAS number 1116433-11-4 N
ATC code None
UNII XQQ2RHV14N YesY
Chemical data
Formula ?
 N (what is this?)  (verify)

Itolizumab (INN, trade name Alzumab) is a ‘first in class’ humanized IgG1 monoclonal antibody developed by Biocon. It selectively targets CD6, a pan T cell marker involved in co-stimulation, adhesion and maturation of T cells. Itolizumab, by binding to CD6, down regulates T cell activation, causes reduction in synthesis of pro-inflammatory cytokines and possibly plays an important role by reducing T cell infiltration at sites of inflammation.[1] A double blind, placebo controlled, phase III treat –Plaq study of itolizumab successfully met the pre-specified primary end-point of significant improvement in PASI-75 (Psoriasis Area and Severity Index) score after 12 weeks of treatment in patients with moderate to severe psoriasis compared to placebo.[2] Biocon has received marketing authorization for the drug from the Drugs Controller General of India (DCGI).[3]

References

  1. http://www.biocon.com/docs/PR_080113.pdf?subLink=news
  2. http://www.thehindubusinessline.com/companies/article2789996.ece
  3. http://www.pharmabiz.com/NewsDetails.aspx?aid=73075&sid=2


This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.